Brian Adams
General Counsel bei RELAY THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 30.04.2024
Profil
Brian R.
Adams is currently the Secretary & Chief Legal Officer at Relay Therapeutics, Inc. He previously worked as the Secretary, Senior Vice President & General Counsel at Keryx Biopharmaceuticals, Inc. from 2014 to 2018, and as the General Counsel at Algeta ASA from 2012 to 2014.
Mr. Adams completed his undergraduate degree at Harvard University and his graduate degree at Columbus School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RELAY THERAPEUTICS, INC.
0,25% | 29.04.2024 | 325 767 ( 0,25% ) | 2 Mio $ | 30.04.2024 |
Aktive Positionen von Brian Adams
| Unternehmen | Position | Beginn |
|---|---|---|
| RELAY THERAPEUTICS, INC. | General Counsel | 01.03.2018 |
Ehemalige bekannte Positionen von Brian Adams
| Unternehmen | Position | Ende |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | General Counsel | 13.03.2018 |
| ALGETA ASA | General Counsel | 01.03.2014 |
Ausbildung von Brian Adams
| Harvard University | Undergraduate Degree |
| Columbus School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RELAY THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
